Abstract
Background: Clustering of various metabolic parameters including abdominal obesity, hyperglycaemia, low high-density lipoprotein cholesterol, elevated triglycerides and hypertension have been used worldwide as metabolic syndrome to predict cardiometabolic risk. Thyroid dysfunction impacts on various levels of these components. Objectives: The purpose of the present review is to summarize available data on thyroid hormone-dependent action on components of the metabolic syndrome. Methods: A PubMed search for any combination of hyperthyroidism, thyrotoxicosis or hypothyroidism and metabolic syndrome, blood pressure, hypertension, hyperlipidaemia, cholesterol, high-density lipoprotein cholesterol, glucose, diabetes mellitus, body weight or visceral fat was performed. We included papers and reviews published between 2000 and today but accepted also frequently cited papers before 2000. Results: There is convincing evidence for a major impact of thyroid function on all components of the metabolic syndrome, reflecting profound alterations of energy homeostasis at many levels. Conclusion: Even though the interactions shown in animal models and man are complex, it is evident that insulin sensitivity is highest and adverse thyroid effects on the metabolic system are lowest in euthyroid conditions.
References
1.
Waring AC, Rodondi N, Harrison S, Kanaya AM, Simonsick EM, Miljkovic I, Satterfield S, Newman AB, Bauer DC: Thyroid function and prevalent and incident metabolic syndrome in older adults: the health, ageing and body composition study. Clin Endocrinol (Oxf) 2012;76:911-918.
2.
Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-1214.
3.
Cameron AJ, Magliano DJ, Zimmet PZ, Welborn TA, Colagiuri S, Tonkin AM, Shaw JE: The metabolic syndrome as a tool for predicting future diabetes: the AUSDIAB study. J Intern Med 2008;264:177-186.
4.
Betterle C, Dal Pra C, Mantero F, Zanchetta R: Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev 2002;23:327-364.
5.
Michels AW, Gottlieb PA: Autoimmune polyglandular syndromes. Nat Rev Endocrinol 2010;6:270-277.
6.
Kahaly GJ: Polyglandular autoimmune syndromes. Eur J Endocrinol 2009;161:11-20.
7.
Alberti KG, Zimmet P, Shaw J: Metabolic syndrome - a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 2006;23:469-480.
8.
Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN: Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011;17:456-520.
9.
Kahaly GJ, Bartalena L, Hegedus L: The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective. Thyroid 2011;21:585-591.
10.
Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA: Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 2012;18:988-1028.
11.
Wikstrom L, Johansson C, Salto C, Barlow C, Campos Barros A, Baas F, Forrest D, Thoren P, Vennstrom B: Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1. EMBO J 1998;17:455-461.
12.
Johansson C, Gothe S, Forrest D, Vennstrom B, Thoren P: Cardiovascular phenotype and temperature control in mice lacking thyroid hormone receptor-beta or both alpha 1 and beta. Am J Physiol 1999;276:H2006-H2012.
13.
Ribeiro MO, Carvalho SD, Schultz JJ, Chiellini G, Scanlan TS, Bianco AC, Brent GA: Thyroid hormone-sympathetic interaction and adaptive thermogenesis are thyroid hormone receptor isoform-specific. J Clin Invest 2001;108:97-105.
14.
Gullberg H, Rudling M, Salto C, Forrest D, Angelin B, Vennstrom B: Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice. Mol Endocrinol 2002;16:1767-1777.
15.
Marrif H, Schifman A, Stepanyan Z, Gillis MA, Calderone A, Weiss RE, Samarut J, Silva JE: Temperature homeostasis in transgenic mice lacking thyroid hormone receptor-alpha gene products. Endocrinology 2005;146:2872-2884.
16.
Weitzel JM, Iwen KA: Coordination of mitochondrial biogenesis by thyroid hormone. Mol Cell Endocrinol 2011;342:1-7.
17.
Coppola A, Liu ZW, Andrews ZB, Paradis E, Roy MC, Friedman JM, Ricquier D, Richard D, Horvath TL, Gao XB, Diano S: A central thermogenic-like mechanism in feeding regulation: an interplay between arcuate nucleus T3 and UCP2. Cell Metab 2007;5:21-33.
18.
Zhang Y, Ma K, Song S, Elam MB, Cook GA, Park EA: Peroxisomal proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1 alpha) enhances the thyroid hormone induction of carnitine palmitoyltransferase I (CPT-I alpha). J Biol Chem 2004;279:53963-53971.
19.
Lopez M, Varela L, Vazquez MJ, Rodriguez-Cuenca S, Gonzalez CR, Velagapudi VR, Morgan DA, Schoenmakers E, Agassandian K, Lage R, Martinez de Morentin PB, Tovar S, Nogueiras R, Carling D, Lelliott C, Gallego R, Oresic M, Chatterjee K, Saha AK, Rahmouni K, Dieguez C, Vidal-Puig A: Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 2010;16:1001-1008.
20.
Klieverik LP, Janssen SF, van Riel A, Foppen E, Bisschop PH, Serlie MJ, Boelen A, Ackermans MT, Sauerwein HP, Fliers E, Kalsbeek A: Thyroid hormone modulates glucose production via a sympathetic pathway from the hypothalamic paraventricular nucleus to the liver. Proc Natl Acad Sci USA 2009;106:5966-5971.
21.
Schofl C, Schleth A, Berger D, Terkamp C, von zur Muhlen A, Brabant G: Sympathoadrenal counterregulation in patients with hypothalamic craniopharyngioma. J Clin Endocrinol Metab 2002;87:624-629.
22.
Sjogren M, Alkemade A, Mittag J, Nordstrom K, Katz A, Rozell B, Westerblad H, Arner A, Vennstrom B: Hypermetabolism in mice caused by the central action of an unliganded thyroid hormone receptor alpha1. EMBO J 2007;26:4535-4545.
23.
Jornayvaz FR, Lee HY, Jurczak MJ, Alves TC, Guebre-Egziabher F, Guigni BA, Zhang D, Samuel VT, Silva JE, Shulman GI: Thyroid hormone receptor-alpha gene knockout mice are protected from diet-induced hepatic insulin resistance. Endocrinology 2012;153:583-591.
24.
Bochukova E, Schoenmakers N, Agostini M, Schoenmakers E, Rajanayagam O, Keogh JM, Henning E, Reinemund J, Gevers E, Sarri M, Downes K, Offiah A, Albanese A, Halsall D, Schwabe JW, Bain M, Lindley K, Muntoni F, Vargha-Khadem F, Dattani M, Farooqi IS, Gurnell M, Chatterjee K: A mutation in the thyroid hormone receptor alpha gene. N Engl J Med 2012;366:243-249.
25.
Mittag J, Lyons DJ, Sallstrom J, Vujovic M, Dudazy-Gralla S, Warner A, Wallis K, Alkemade A, Nordstrom K, Monyer H, Broberger C, Arner A, Vennstrom B: Thyroid hormone is required for hypothalamic neurons regulating cardiovascular functions. J Clin Invest 2013;123:509-516.
26.
Weinstein SP, O'Boyle E, Fisher M, Haber RS: Regulation of GLUT2 glucose transporter expression in liver by thyroid hormone: evidence for hormonal regulation of the hepatic glucose transport system. Endocrinology 1994;135:649-654.
27.
Weinstein SP, O'Boyle E, Haber RS: Thyroid hormone increases basal and insulin-stimulated glucose transport in skeletal muscle. The role of GLUT4 glucose transporter expression. Diabetes 1994;43:1185-1189.
28.
Dimitriadis GD, Raptis SA: Thyroid hormone excess and glucose intolerance. Exp Clin Endocrinol Diabetes 2001;109(suppl 2):S225-S239.
29.
Diamant S, Gorin E, Shafrir E: Enzyme activities related to fatty-acid synthesis in liver and adipose tissue of rats treated with triiodothyronine. Eur J Biochem 1972;26:553-559.
30.
Loose DS, Cameron DK, Short HP, Hanson RW: Thyroid hormone regulates transcription of the gene for cytosolic phosphoenolpyruvate carboxykinase (GTP) in rat liver. Biochemistry 1985;24:4509-4512.
31.
Song MK, Dozin B, Grieco D, Rall JE, Nikodem VM: Transcriptional activation and stabilization of malic enzyme mRNA precursor by thyroid hormone. J Biol Chem 1988;263:17970-17974.
32.
Carvalho SD, Negrao N, Bianco AC: Hormonal regulation of malic enzyme and glucose-6-phosphate dehydrogenase in brown adipose tissue. Am J Physiol 1993;264:E874-E881.
33.
Zabrocka L, Klimek J, Swierczynski J: Pharmacological doses of triiodothyronine upregulate lipogenic enzyme gene expression in rat white adipose tissue. Horm Metab Res 2006;38:63-68.
34.
Macek Jilkova Z, Pavelka S, Flachs P, Hensler M, Kus V, Kopecky J: Modulation of type I iodothyronine 5′′-deiodinase activity in white adipose tissue by nutrition: possible involvement of leptin. Physiol Res 2010;59:561-569.
35.
Sinha RA, You SH, Zhou J, Siddique MM, Bay BH, Zhu X, Privalsky ML, Cheng SY, Stevens RD, Summers SA, Newgard CB, Lazar MA, Yen PM: Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. J Clin Invest 2012;122:2428-2438.
36.
Ortega FJ, Jilkova ZM, Moreno-Navarrete JM, Pavelka S, Rodriguez-Hermosa JI, Kopeck Ygrave J, Fernandez-Real JM: Type I iodothyronine 5′′-deiodinase mrna and activity is increased in adipose tissue of obese subjects. Int J Obes (Lond) 2012;36:320-324.
37.
Marsili A, Aguayo-Mazzucato C, Chen T, Kumar A, Chung M, Lunsford EP, Harney JW, Van-Tran T, Gianetti E, Ramadan W, Chou C, Bonner-Weir S, Larsen PR, Silva JE, Zavacki AM: Mice with a targeted deletion of the type 2 deiodinase are insulin resistant and susceptible to diet induced obesity. PLoS One 2011;6:e20832.
38.
Klieverik LP, Coomans CP, Endert E, Sauerwein HP, Havekes LM, Voshol PJ, Rensen PC, Romijn JA, Kalsbeek A, Fliers E: Thyroid hormone effects on whole-body energy homeostasis and tissue-specific fatty acid uptake in vivo. Endocrinology 2009;150:5639-5648.
39.
Furuya F, Shimura H, Yamashita S, Endo T, Kobayashi T: Liganded thyroid hormone receptor-alpha enhances proliferation of pancreatic beta-cells. J Biol Chem 2010;285:24477-24486.
40.
Lin Y, Sun Z: Thyroid hormone potentiates insulin signaling and attenuates hyperglycemia and insulin resistance in a mouse model of type 2 diabetes. Br J Pharmacol 2011;162:597-610.
41.
Blanchet E, Bertrand C, Annicotte JS, Schlernitzauer A, Pessemesse L, Levin J, Fouret G, Feillet-Coudray C, Bonafos B, Fajas L, Cabello G, Wrutniak-Cabello C, Casas F: Mitochondrial T3 receptor P43 regulates insulin secretion and glucose homeostasis. FASEB J 2012;26:40-50.
42.
Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, Kaul MG, Tromsdorf UI, Weller H, Waurisch C, Eychmuller A, Gordts PL, Rinninger F, Bruegelmann K, Freund B, Nielsen P, Merkel M, Heeren J: Brown adipose tissue activity controls triglyceride clearance. Nat Med 2011;17:200-205.
43.
de Jesus LA, Carvalho SD, Ribeiro MO, Schneider M, Kim SW, Harney JW, Larsen PR, Bianco AC: The type 2 iodothyronine deiodinase is essential for adaptive thermogenesis in brown adipose tissue. J Clin Invest 2001;108:1379-1385.
44.
Christoffolete MA, Linardi CC, de Jesus L, Ebina KN, Carvalho SD, Ribeiro MO, Rabelo R, Curcio C, Martins L, Kimura ET, Bianco AC: Mice with targeted disruption of the dio2 gene have cold-induced overexpression of the uncoupling protein 1 gene but fail to increase brown adipose tissue lipogenesis and adaptive thermogenesis. Diabetes 2004;53:577-584.
45.
Pessemesse L, Schlernitzauer A, Sar C, Levin J, Grandemange S, Seyer P, Favier FB, Kaminski S, Cabello G, Wrutniak-Cabello C, Casas F: Depletion of the P43 mitochondrial T3 receptor in mice affects skeletal muscle development and activity. FASEB J 2012;26:748-756.
46.
Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J: Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006;439:484-489.
47.
Ockenga J, Valentini L, Schuetz T, Wohlgemuth F, Glaeser S, Omar A, Kasim E, duPlessis D, Featherstone K, Davis JR, Tietge UJ, Kroencke T, Biebermann H, Kohrle J, Brabant G: Plasma bile acids are associated with energy expenditure and thyroid function in humans. J Clin Endocrinol Metab 2012;97:535-542.
48.
Watanabe M, Morimoto K, Houten SM, Kaneko-Iwasaki N, Sugizaki T, Horai Y, Mataki C, Sato H, Murahashi K, Arita E, Schoonjans K, Suzuki T, Itoh H, Auwerx J: Bile acid binding resin improves metabolic control through the induction of energy expenditure. PLoS One 2012;7:e38286.
49.
Jequier E: Leptin signaling, adiposity, and energy balance. Ann NY Acad Sci 2002;967:379-388.
50.
Legradi G, Emerson CH, Ahima RS, Flier JS, Lechan RM: Leptin prevents fasting-induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. Endocrinology 1997;138:2569-2576.
51.
Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS: Role of leptin in the neuroendocrine response to fasting. Nature 1996;382:250-252.
52.
Duntas L, Micic D: Adiposopathy and thyroid disease: tracing the pathway to cardiovascular risk. Expert Rev Cardiovasc Ther 2012;10:797-803.
53.
Lee YK, Kim JE, Oh HJ, Park KS, Kim SK, Park SW, Kim MJ, Cho YW: Serum TSH level in healthy Koreans and the association of TSH with serum lipid concentration and metabolic syndrome. Korean J Intern Med 2011;26:432-439.
54.
Park SB, Choi HC, Joo NS: The relation of thyroid function to components of the metabolic syndrome in Korean men and women. J Korean Med Sci 2011;26:540-545.
55.
de Moura Souza A, Sichieri R: Association between serum TSH concentration within the normal range and adiposity. Eur J Endocrinol 2011;165:11-15.
56.
Ittermann T, Thamm M, Schipf S, John U, Rettig R, Volzke H: Relationship of smoking and/or passive exposure to tobacco smoke on the association between serum thyroid-stimulating hormone and body mass index in large groups of adolescents and children. Thyroid 2013;23:262-268.
57.
Muscogiuri G, Sorice GP, Mezza T, Prioletta A, Lassandro AP, Pirronti T, Della Casa S, Pontecorvi A, Giaccari A: High-normal tsh values in obesity: is it insulin resistance or adipose tissue's guilt? Obesity (Silver Spring) 2013;21:101-106.
58.
Kitahara CM, Platz EA, Ladenson PW, Mondul AM, Menke A, Berrington de Gonzalez A: Body fatness and markers of thyroid function among US men and women. PLoS One 2012;7:e34979.
59.
Reinehr T, Isa A, de Sousa G, Dieffenbach R, Andler W: Thyroid hormones and their relation to weight status. Horm Res 2008;70:51-57.
60.
Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS: Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004;351:987-997.
61.
Reinehr T, Andler W: Thyroid hormones before and after weight loss in obesity. Arch Dis Child 2002;87:320-323.
62.
Tagliaferri M, Berselli ME, Calo G, Minocci A, Savia G, Petroni ML, Viberti GC, Liuzzi A: Subclinical hypothyroidism in obese patients: relation to resting energy expenditure, serum leptin, body composition, and lipid profile. Obes Res 2001;9:196-201.
63.
al-Adsani H, Hoffer LJ, Silva JE: Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab 1997;82:1118-1125.
64.
Jonklaas J, Nsouli-Maktabi H: Weight changes in euthyroid patients undergoing thyroidectomy. Thyroid 2011;21:1343-1351.
65.
Klieverik LP, Kalsbeek A, Ackermans MT, Sauerwein HP, Wiersinga WM, Fliers E: Energy homeostasis and body weight before and after cessation of block and replacement therapy in euthyroid patients with graves' disease. Int J Endocrinol 2011;2011:715370.
66.
Appelhof BC, Fliers E, Wekking EM, Schene AH, Huyser J, Tijssen JG, Endert E, van Weert HC, Wiersinga WM: Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab 2005;90:2666-2674.
67.
Celi FS, Zemskova M, Linderman JD, Smith S, Drinkard B, Sachdev V, Skarulis MC, Kozlosky M, Csako G, Costello R, Pucino F: Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. J Clin Endocrinol Metab 2011;96:3466-3474.
68.
Ittermann T, Thamm M, Wallaschofski H, Rettig R, Volzke H: Serum thyroid-stimulating hormone levels are associated with blood pressure in children and adolescents. J Clin Endocrinol Metab 2012;97:828-834.
69.
Cai Y, Ren Y, Shi J: Blood pressure levels in patients with subclinical thyroid dysfunction: a meta-analysis of cross-sectional data. Hypertens Res 2011;34:1098-1105.
70.
Mason RL, Hunt HM, Hurxthal L: Blood cholesterol values in hyperthyroidism and hypothyroidism and their significance. N Engl J Med 1930;203:1273-1278.
71.
Duntas LH, Brenta G: The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am 2012;96:269-281.
72.
Pearce EN: Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab 2012;97:326-333.
73.
Asvold BO, Vatten LJ, Nilsen TI, Bjoro T: The association between tsh within the reference range and serum lipid concentrations in a population-based study. The Hunt study. Eur J Endocrinol 2007;156:181-186.
74.
Danese MD, Ladenson PW, Meinert CL, Powe NR: Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure. A quantitative review of the literature. J Clin Endocrinol Metab 2000;85:2993-3001.
75.
Prieur X, Huby T, Coste H, Schaap FG, Chapman MJ, Rodriguez JC: Thyroid hormone regulates the hypotriglyceridemic gene APOA5. J Biol Chem 2005;280:27533-27543.
76.
Jenkins RC, Valcavi R, Zini M, Frasoldati A, Heller SR, Camacho-Hubner C, Gibson JM, Westwood M, Ross RJ: Association of elevated insulin-like growth factor binding protein-1 with insulin resistance in hyperthyroidism. Clin Endocrinol (Oxf) 2000;52:187-195.
77.
Maratou E, Hadjidakis DJ, Peppa M, Alevizaki M, Tsegka K, Lambadiari V, Mitrou P, Boutati E, Kollias A, Economopoulos T, Raptis SA, Dimitriadis G: Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism. Eur J Endocrinol 2010;163:625-630.
78.
Mitrou P, Raptis SA, Dimitriadis G: Insulin action in hyperthyroidism: a focus on muscle and adipose tissue. Endocr Rev 2010;31:663-679.
79.
Maratou E, Hadjidakis DJ, Kollias A, Tsegka K, Peppa M, Alevizaki M, Mitrou P, Lambadiari V, Boutati E, Nikzas D, Tountas N, Economopoulos T, Raptis SA, Dimitriadis G: Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol 2009;160:785-790.
80.
Dimitriadis G, Maratou E, Alevizaki M, Boutati E, Psara K, Papasteriades C, Raptis SA: Thyroid hormone excess increases basal and insulin-stimulated recruitment of GLUT3 glucose transporters on cell surface. Horm Metab Res 2005;37:15-20.
81.
Visser WE, Heemstra KA, Swagemakers SM, Ozgur Z, Corssmit EP, Burggraaf J, van Ijcken WF, van der Spek PJ, Smit JW, Visser TJ: Physiological thyroid hormone levels regulate numerous skeletal muscle transcripts. J Clin Endocrinol Metab 2009;94:3487-3496.
82.
Dimitriadis G, Mitrou P, Lambadiari V, Boutati E, Maratou E, Panagiotakos DB, Koukkou E, Tzanela M, Thalassinos N, Raptis SA: Insulin action in adipose tissue and muscle in hypothyroidism. J Clin Endocrinol Metab 2006;91:4930-4937.
83.
Stanicka S, Vondra K, Pelikanova T, Vlcek P, Hill M, Zamrazil V: Insulin sensitivity and counter-regulatory hormones in hypothyroidism and during thyroid hormone replacement therapy. Clin Chem Lab Med 2005;43:715-720.
84.
Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH: Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 2007;92:491-496.
85.
Skarulis MC, Celi FS, Mueller E, Zemskova M, Malek R, Hugendubler L, Cochran C, Solomon J, Chen C, Gorden P: Thyroid hormone induced brown adipose tissue and amelioration of diabetes in a patient with extreme insulin resistance. J Clin Endocrinol Metab 2010;95:256-262.
© 2013 European Thyroid Association Published by S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
